Clinical development of anticancer agents incorporating micelles in oncological treatment

Abstract

Anticancer agents categorized in DDS based on nanotechnology have been approved. Regarding a pipeline of clinical development of micelle carrier system, several clinical trials are now underway not only in Japan but also in other countries. Among them, especially in this chapter, clinical status of NK105, paclitaxel incorporating micelle, NC-6004, cisplatin incorporating micelle, and NC-6300, epirubicin incorporating micelle will be described.